763 results about "Microbiome" patented technology

The present invention describes changes in bacterial gastrointestinal, cutaneous and nasal microbiota associated various mammalian medical conditions. Described are diagnostic tests that arise from combining phylogenetic information about the families, genus, and species of the microbiome and their relative abundance with the metabolic information contained in the metatranscriptome to determine the presence and absence of a disease or medical condition. Provided are compositions of bacteria, co-cultures of bacteria and a carrier for use in treating the disclosed medical conditions. The described compositions restore or correct disease- or medical condition-related imbalances in the microbiome profile with culture-conditioned formulations in which the transcriptome activity of the administered organisms is optimized. Alternatively, formulations of metabolites that drive changes in the metatranscriptome native to the mammal that treat disease or a medical condition or restore health are taught.

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and/or to develop and monitor the outcome of therapeutic treatments. An exemplary disease/condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

Methods of modulating body fat or weight loss are presented Nucleic acid and protein microarrays that comprise biomolecules associated with an obese host microbiome or a lean host microbiome are utilized for analysis.

A material substrate having at least part of a surface treated with an antimicrobial composition is described. The antimicrobial composition exhibits at least a 3 log₁₀ CFU reduction within a period of about 30 minutes after contact with various species of a broad spectrum of microorganisms. The substrate can be a nonwoven material that has good fluid barrier properties, which can be used in protective garments and sheets. Methods for manufacturing and imparting the antimicrobial treatment to the substrate are also provided.

The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The disclosure provides compositions and methods for the treatment of skin disorders using microbial compositions to a subject.

The present disclosure provides methods for profiling a microbiome and therapeutic compositions for treatment. Additionally, the methods, systems, compositions and kits provided herein are directed to assessing or predicting health status in a subject. Some of the embodiments include generating a report.

Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

Facilities operations can be conducted more safely, efficiently, and cost-effectively by monitoring changes in the facility microbiome and intervening when those changes indicate the likelihood of a deleterious effect there-from.

The present invention relates to antimicrobial compositions that provide enhanced immediate and residual antiviral and antibacterial efficacy. The antimicrobial compositions of the present invention provide, when used, residual efficacy against Gram-negative bacteria, Gram-positive bacteria and viruses, fungi, and enhanced immediate pathogen reduction not found in the prior art. The compositions of the present invention comprise: a) a safe and effective amount of a benzoic acid analog; b) a safe and effective amount of a metal salt; and c) a dermatologically acceptable carrier of the acid and salt, wherein the pH of the composition is About 1-about 7. The invention also relates to methods of using the compositions of the invention and antimicrobial products comprising the compositions of the invention.

Methods, compositions, and systems are provided for detecting one or more a gastrointestinal issues by characterizing the microbiome of an individual, monitoring such effects, and/or determining, displaying, or promoting a therapy for the gastrointestinal issue. Methods, compositions, and systems are also provided for generating and comparing microbiome composition and/or functional diversity datasets. Methods, compositions, and systems are also provided for generating a characterization model and/or therapy model for constipation issues, diarrhea issues, hemorrhoids issues, bloating issues, and lactose intolerance issues.

Therapeutic antimicrobial compositions and methods for providing enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respitory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, therapeutic antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain, and therapeutic methods of use thereof.

A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs. In particular, decreased pathogenic organism infectivity, morbidity, and mortality is accomplished by contacting the pathogenic organism with an oil-in-water nanoemulsion comprising an oil, an organic solvent, and a surfactant dispersed in an aqueous phase.

Provided is a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. Further provided is a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. Further provided is a use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

An elastomeric article having reducing microbe affinity and transmission and methods for applying and immobilizing antimicrobial compounds to the elastomeric substrate surface are disclosed. The elastomeric article has a body formed of a natural or synthetic polymer latex having an outer surface and an inner surface. The body has a coating of an antimicrobial agent over at least a portion of said outer surface. The treatment involves applying according to either a spraying or dipping process an antimicrobial polymer or composition to a surface of the elastomeric substrate; binding the antimicrobial composition to the surface in a manner such that said treat antimicrobial coating passes either one or another or both versions of a zone of inhibition test, such test including: a) a dry-leaching or agar-plate-based contact test, according to AATCC 147 protocol, or b) a wet-leaching or dynamic shake flask test according to ASTM E-2149-01 protocol. The substrate is further subject to a rapid germicidal contact-transfer test of relatively short duration. The antimicrobial polymer can include an organosilane quaternary ammonium or a biguanide compound which can disrupt the ionic charges of microbial cellular membranes.

Antimicrobial (e.g., moldicide, fungicide, bacteriacide, and virucide) compositions are disclosed. Methods of making and using antimicrobial (e.g., moldicide, fungicide, bacteriacide, and virucide) compositions are also disclosed.

The invention discloses a plant extract and synergist contained antimicrobial composition. The composition contains a plant extract (A), a synergist (B), a mildew preventive (C), an antiseptic (D) and a solvent (E). The composition disclosed by the invention has a good inhibiting effect on bacteria and fungi (molds nod saccharomycetes); through the synergistic effect of all the components, the consumption of the traditional chemical antiseptic IPBC (Iodopropynyl Butylcarbamate) or nipagin esters is remarkably reduced, the safety in using the composition is improved, the irritation is reduced, and the possible risks are reduced. Meanwhile, the antiseptic is compounded in the composition, so that the antibacterial spectrum of an antiseptic system of the composition is effectively expanded, and the bacteriostatic ability is enhanced.

This invention relates to a fecal microbiome transplant material preparation method and apparatus for the preparation of fecal material for a fecal transplant. A healthy patient's stool is collected and deposited in a first container which has its open end attached to a second container to form a fecal processing device. Blender blades are positioned in the second container and a filter is mounted therein. Liquid is injected into the second container through a syringe port having a valve therein to block the escape of liquid from the connected containers. Intake and exhaust ports allow air to enter and escape from the connected containers while blocking the escape of liquid. The liquid and fecal matter in the connected containers is blended and the blended liquid is strained through the filter in the second container and removed through the syringe port for use in a fecal transplant.